Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

Leukemia Research

Volumn 33, Issue 11, 2009, Pages 1481-1484

  Vega Ruiz, Arturo ^a   Cortes, Jorge E ^a   Sever, Matjaz ^a   Manshouri, Taghi ^a   Quintás Cardama, Alfonso ^a   Luthra, Raja ^a   Kantarjian, Hagop M ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Imatinib mesylate; KIT D816V mutation; Systemic mastocytosis

Indexed keywords

CYCLOSPORIN; IMATINIB; MEMBRANE RECEPTOR; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE; STEM CELL FACTOR RECEPTOR; TRYPTASE;

ADULT; AGED; ANEMIA; ARTICLE; ASCITES; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PUVA; RASH; SYSTEMIC MASTOCYTOSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; PIPERAZINES; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; TREATMENT OUTCOME;

EID: 68649118339     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.12.020     Document Type: Article

References (11)

1. Horny H.P., Sotlar K., and Valent P. Mastocytosis: state of the art. Pathobiology 74 (2007) 121-132
2. Patnaik M.M., Tefferi A., and Pardanani A. Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders. Curr Cancer Drug Target 7 (2007) 492-503
3. Furitsu T., TsujimuraT, Tono T., et al. Identifications of mutations in the coding sequence of the proto-oncogen c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92 (1993) 1736-1744
4. Quintas-Cardama A., Aribi A., Cortes J., et al. Novel approaches in the treatment of systemic mastocytosis. Cancer 107 (2006) 1429-1439
5. Ma Y., Zeng S., Metcalfe D.D., et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99 (2002) 1741-1744
6. Droogendijk H.J., Kluin-Nelemans H.J., van Doormaal J.J., et al. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer 107 (2006) 345-351
7. Valent P., Horny H.P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25 7 (2001) 603-625
8. Piccaluga P.P., Rondoni M., Paolini S., et al. Imatinib mesylate in the treatment of hematologic malignancies. Expert Opin Biol Ther 7 (2007) 1597-1611
9. Pardanani A., Elliot M., Reeder T., et al. Imatinib for systemic mast cell disease. Lancet 362 (2003) 535-537
10. Akin C., Fumo G., Yavuz A.S., et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103 (2004) 3222-3225
11. Frost M.J., Ferrao P.T., Hughes T.P., et al. Juxtamembrane mutant V560Gkit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase mutant D816Vkit is resistant. Mol Cancer Ther 1 (2002) 1115-1124